- Home
- CSGP vs BBIO Comparison
CSGP vs BBIO Comparison
Compare CSGP & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CSGP | BBIO |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4B | 12.7B |
| IPO Year | 1998 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CSGP | BBIO |
|---|---|---|
| Price | $29.63 | $81.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 25 |
| Target Price | $60.57 | ★ $86.33 |
| AVG Volume (30 Days) | ★ 6.9M | 3.9M |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $965,230,000.00 | $502,076,000.00 |
| Revenue This Year | $19.71 | $89.45 |
| Revenue Next Year | $12.40 | $73.78 |
| P/E Ratio | $3,047.50 | ★ N/A |
| Revenue Growth | 15.23 | ★ 126.26 |
| 52 Week Low | $26.68 | $42.09 |
| 52 Week High | $97.43 | $93.42 |
Technical Indicators
Market Signals| Indicator | CSGP | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 47.63 | 60.74 |
| Support Level | $28.18 | $62.93 |
| Resistance Level | $34.84 | $84.85 |
| Average True Range (ATR) | 1.26 | 3.51 |
| MACD | 0.22 | 0.28 |
| Stochastic Oscillator | 68.79 | 48.35 |
Price Performance
Historical ComparisonAbout CSGP CoStar Group Inc.
CoStar Group is a global provider of proprietary information, analytics, and online marketplaces serving both commercial and residential real estate. The firm operates through a diverse portfolio of brands, including CoStar Suite for commercial real estate research, LoopNet for commercial listings, Apartments.com for multifamily rentals, and Homes.com for residential brokerage. It primarily sells high-margin software-as-a-service subscriptions that provide institutional clients with forensic property data and premium advertising visibility. With operations across North America, Europe, and Asia-Pacific, CoStar maintains the industry's most comprehensive centralized real estate database, functioning as a critical information utility for brokers, lenders, and owners worldwide.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.